中药辅助治疗降低结肠癌患者慢性肝炎发病率:台湾人群队列研究
本研究利用台湾全民健康保险研究数据库,评估中药辅助治疗是否降低接受常规西药治疗的结肠癌患者慢性肝炎发病率。共分析155例匹配患者,结果显示中药治疗组慢性肝炎发病率显著降低(HR=0.53;95%CI:0.38-0.74),且五年累积发病率亦降低。
要点
- 中药辅助治疗与结肠癌患者慢性肝炎发病率降低显著相关(HR=0.53)。
- 保护效应在年龄、性别、合并症及治疗方式分层中均具统计学显著性。
- 中药治疗组五年累积慢性肝炎发病率亦降低。
核心结论
- 中药作为辅助疗法可能对结肠癌患者具有显著的肝脏保护作用。
研究设计与样本
- 台湾全国性回顾性队列研究,使用全民健康保险研究数据库,1997至2010年诊断为结肠癌的患者共61676例,经年龄、性别随机等量匹配并排除特定条件后,最终分析155例患者数据。
主要发现
- 与未使用中药者相比,使用中药的结肠癌患者慢性肝炎发病率显著降低(HR=0.53;95%CI:0.38-0.74),经多变量调整。
- 中药治疗的保护效应在年龄、性别、合并症和治疗方式分层中均具有统计学显著性。
- 接受中药治疗的结肠癌患者五年期间慢性肝炎累积发病率亦降低。
- 研究提供了结肠癌患者最常用的十种单味药和复方,并识别出八种单味药和五种复方与慢性肝炎发病率显著降低相关。
临床怎么用
- 在常规西药治疗基础上,可考虑将中药作为辅助疗法,以期降低结肠癌患者慢性肝炎的发生风险。
局限性
- 本研究为回顾性队列研究,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: There is a decided lack of in-depth studies to evaluate the effectiveness of Chinese Herbal Medicine (CHM) as an adjuvant therapy on the incidence of chronic hepatitis in patients with colon cancer. AIM OF THE STUDY: The aim of this study is to assess whether CHM treatment decreased the incidence of chronic hepatitis in colon cancer patients who received conventional Western medical treatment. MATERIALS AND METHODS: A Taiwanese nationwide population-based study of colon cancer patients receiving Western medicine treatment in conjunction with CHM treatment, using data provided by the National Health Insurance (NHI) Research Database, was conducted. A total of 61676 patients were diagnosed with colon cancer in Taiwan within the defined study period, from 1997 to 2010. After randomly equal matching for age, sex, excluding patients younger than 18 years of age, chronic hepatitis before colon cancer diagnosis date, receiving acupuncture and/or moxibustion and taking CHM for less than 30 days, data from 155 patients were analyzed. Hazard ratios of incidence rate of chronic hepatitis were used to determine the influence of CHM and the therapeutic potential of herbal products in treating patients with colon cancer. RESULTS: CHM used for patients with colon cancer exhibited significantly decreased incidence rates of chronic hepatitis [hazard ratio (HR)=0.53; 95% confidence interval (CI):0.38-0.74], with multivariate adjustment, compared to those without CHM use. The protective effect of CHM treatment with statistical significance across the stratification of age, gender, co-morbidity and treatment modality was noted. The cumulative incidence of chronic hepatitis was also reduced in patients with colon cancer receiving CHM treatment during a five-year period. In this study, we provide the ten most used single herbs and herbal formulas that were prescribed for patients with colon cancer; moreover, we identify the eight single herbs and five formulas used in CHM treatment which significantly decreased incidence of chronic hepatitis among colon cancer patients. CONCLUSIONS: This nationwide retrospective cohort study determined that therapy using CHM as an adjuvant modality may have a significant impact on liver protection in patients with colon cancer.
引用
- Lin TH, Yen HR, Chiang JH, et al. The use of Chinese herbal medicine as an adjuvant therapy to reduce incidence of chronic hepatitis in colon cancer patients: A Taiwanese population-based cohort study. J Ethnopharmacol. 2017. PMID: 28330722. doi:10.1016/j.jep.2017.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。